NASDAQ / LIVE COMPANY INTELLIGENCE

Tarsus Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERTARS
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / TARS COVERAGE

What’s moving Tarsus Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Yahoo Finance

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Investors are testing whether Tarsus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

The story matters when it changes Tarsus Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

Investors are testing whether Tarsus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts

Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts

Investors are testing whether Tarsus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

Investors are testing whether Tarsus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

The story matters when it changes Tarsus Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors

The story matters when it changes Tarsus Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest TARS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-04 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-13 · Period 2026-07-13SEC ↗8-KMaterial company eventFiled 2026-07-08 · Period 2026-07-06SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-25SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-25SEC ↗4Official SEC filingFiled 2026-06-29 · Period 2026-06-25SEC ↗
EARNINGS / QUARTERLY TRACKER

Tarsus Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.